Developing a pipeline of ground-breaking inhaled cannabinoid products

Our product portfolio offers a comprehensive range of pharmaceutical cannabinoid treatment options

Senzer’s innovative product range offers a selection of advanced delivery mechanisms for pharmaceutical cannabinoids. Our pipeline includes patent-protected drug-device combination products, based on Senzer’s proven inhalation technology and proprietary formulations.

Devices are manufactured at a specialised facility located in the UK, and all manufacturing complies with strict GMP, ISO 13485, FDA’s CFR Title 21 Part 820 and the EU’s Medical Device Directive 93/42/EEC regulations.

Candex Dronabinol Inhaler

Dronabinol (Tetrahydrocannabinol)

  • Fast acting treatment for chemotherapy-induced nausea and vomiting (proposed primary indication).
  • Multi-dose pack and inhaler, based on Senzer successful proprietary SiDD™ delivery platform.
  • The product is expected to have enhanced bioavailability relative to oral forms resulting in a lower effective dose and faster onset of action.

Cannabidiol

  • Fast acting treatment for breakthrough neuropathic pain (proposed primary indication
  • Multi-dose pack and inhaler, based on Senzer successful proprietary SiDD delivery platform.
  • The product is expected to have enhanced bioavailability relative to oral forms resulting in a lower effective dose and faster onset of action.

How to use

Remove the inhaler from the all-in-one child resistant refill pack.

Charge the device with a single dose of the medicine by inserting it into the bottom of the refill pack.

Inhale the medicine by sucking air through the device, the dose will be delivered over 3 to 5 gentle breaths.

The dose delivery is customised to a patients’ respiratory ability.

The above dosages and indications are preliminary and indicative only and have not been evaluated by any relevant regulatory authority including the Food & Drug Administration. Senzer’s products are not currently available for purchase.